Therapeutic targeting of SET1B/compass pathway for treating cancers
US10308698B2 · kind B2 · utility
1Cited by
0References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 10, 2017 |
| Grant date | Jun 4, 2019 |
| Priority date | — |
| Expiry date | Jul 10, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/178
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are methods for treating Set1/COMPASS-associated cancers characterized by expression of Set1B/COMPASS. The methods typically include administering a therapeutic amount of an inhibitor of the Set1B/COMPASS pathway and/or an agonist for a target that is negatively regulated by the Set1B/COMPASS pathway.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.